Fortune 500's top 10 healthcare companies

In 2022, despite an uncertain economic landscape, healthcare companies continued to rank among Fortune 500’s biggest corporations that brought in the most revenue for the fiscal year.  

Released on June 5, the 69th annual list is topped by Walmart, Amazon and Exxon Mobil, but includes a substantial number of healthcare companies. Among those are 12 specializing in medical facilities, eight health insurance and managed care companies, and 14 pharmaceutical and health service companies. 

UnitedHealth Group led the healthcare rankings, bringing in a total of $324.16 billion in revenue for 2022; the insurance giant was followed by 79 additional healthcare companies that made Fortune 500’s cut. 

Ranked by their 2022 revenue, the top 10 healthcare companies on the list are as follows: 

  1. UnitedHealth Group (ranked 5th on Fortune): $324.16 billion, change of 12.7% from 2021. 

  1. CVS Health (ranked 6th): $322.46 billion, change of 10.4%.

  1. McKesson (ranked 9th): $263.96 billion, change of 10.8%. 

  1. AmerisourceBergen (ranked 11th): $238.58 billion, change of 11.5%. 

  1. Cardinal Health (ranked 14th): $181.36 billion, change of 11.6%. 

  1. Cigna (ranked 16th): $180.51 billion, change of 3.7%. 

  1. Elevance Health (ranked 22nd): $156.59 billion, change of 13%. 

  1. Centene (ranked 25th): $144.54 billion, change of 14.7%. 

  1. Pfizer (ranked 38th): $100.33 billion, change of 23.4%. 

  1. Johnson & Johnson (ranked 40th): $94.94 billion, change of 1.2%. 

Among numerous other notable big name healthcare leaders on the list are Humana, HCA Healthcare, Merck, Eli Lilly, Gilead Sciences and Moderna, just to name a few. HCA Healthcare’s revenue led companies specializing in facilities, garnering a total of $60.23 billion, up 2.5% year over year. UnitedHealth Group topped the list of insurance companies, while CVS Health bested all other pharmaceutical providers. 

For more insight into the report, click here. To view the full report, click here (paywall). 

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.